CSS
ADAP

Cubist Systematic Strategies’s Adaptimmune Therapeutics ADAP Stock Holding History

Cubist Systematic Strategies’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-675,882
Closed -$1.07M – 2879
2024
Q1 		$1.07M Buy
675,882
+641,275
+1,853% +$774K 0.01% 2114
2023
Q4 		$27.4K Buy
+34,607
New +$19.5K ﹤0.01% 3324
2023
Q3 		– Sell
-10,049
Closed -$9.29K – 3273
2023
Q2 		$9.29K Sell
10,049
-2,518
-20% -$3K ﹤0.01% 3262
2023
Q1 		$13.7K Sell
12,567
-10,061
-44% -$15.6K ﹤0.01% 3697
2022
Q4 		$33K Buy
+22,628
New +$36.6K ﹤0.01% 3954
2022
Q3 		– Sell
-2,094
Closed -$4K – 4387
2022
Q2 		$4K Sell
2,094
-42,106
-95% -$72.3K ﹤0.01% 4300
2022
Q1 		$91K Sell
44,200
-36,321
-45% -$98K ﹤0.01% 3270
2021
Q4 		$302K Buy
80,521
+22,568
+39% +$103K ﹤0.01% 2794
2021
Q3 		$300K Buy
57,953
+48,054
+485% +$216K ﹤0.01% 2352
2021
Q2 		$42K Buy
9,899
+5,699
+136% +$27.7K ﹤0.01% 2805
2021
Q1 		$22K Sell
4,200
-17,482
-81% -$100K ﹤0.01% 2771
2020
Q4 		$117K Buy
+21,682
New +$118K ﹤0.01% 2379
2020
Q3 		– Sell
-19,744
Closed -$198K – 2467
2020
Q2 		$198K Buy
+19,744
New +$124K ﹤0.01% 2039
2019
Q1 		– Sell
-15,233
Closed -$88K – 2216
2018
Q4 		$88K Buy
15,233
+3,492
+30% +$25.8K ﹤0.01% 1781
2018
Q3 		$159K Sell
11,741
-8,603
-42% -$90.2K 0.01% 1481
2018
Q2 		$241K Sell
20,344
-2,271
-10% -$28.3K 0.01% 1221
2018
Q1 		$254K Buy
22,615
+3,245
+17% +$28.4K 0.01% 1254
2017
Q4 		$129K Sell
19,370
-2,799
-13% -$21.6K 0.01% 1646
2017
Q3 		$182K Buy
+22,169
New +$138K 0.01% 1485
2017
Q2 		– Sell
-1,200
Closed -$7K – 1647
2017
Q1 		$7K Buy
+1,200
New +$5.25K ﹤0.01% 1572
2016
Q1 		– Sell
-7
Closed – – 1580
2015
Q4 		$0 Buy
+7
New +$69 ﹤0.01% 1738

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Cubist Systematic Strategies's ADAP Position: Q2 2024 in Review

Cubist Systematic Strategies sold out of Adaptimmune Therapeutics (ADAP) in Q2 2024, closing a stake of 675,882 shares — an estimated $1.07M sold.

Cubist Systematic Strategies first reported a position in ADAP in Q4 2015 and held it in 21 quarters. The position peaked at $1.07M in Q1 2024. 76 funds tracked by Wall St. Rank hold ADAP as of Q2 2024.

  • Cubist Systematic Strategies reported no remaining Adaptimmune Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 675,882 Adaptimmune Therapeutics shares in Q2 2024, an estimated $1.07M.
  • Cubist Systematic Strategies first reported a position in Adaptimmune Therapeutics in Q4 2015 and held it in 21 quarters.
  • Cubist Systematic Strategies's Adaptimmune Therapeutics position peaked at $1.07M in Q1 2024.
  • 76 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2024.

Based on Cubist Systematic Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.